



Oxidative stress and immune aberrancies in attention-deficit/hyperactivity disorder (ADHD): a case–control comparison

Annelies A. J. Verlaet¹ · Annelies Breynaert¹ · Berten Ceulemans² · Tess De Bruyne¹ · Erik Franssen³ · Luc Pieters¹ · Huub F. J. Savelkoul⁴ · Nina Hermans¹

Received: 15 June 2018 / Accepted: 13 October 2018 / Published online: 22 October 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Abstract

The objective of this study is to compare oxidative stress and immune biomarkers between attention-deficit/hyperactivity disorder (ADHD) patients and controls without ADHD. A case–control comparison between 57 paediatric (6–12 years) untreated ADHD patients from the Antwerp University Hospital and 69 controls without ADHD from random schools in Flanders, Belgium, was conducted. Erythrocyte glutathione (GSH) and plasma lipid-soluble antioxidants (retinol, α -tocopherol, γ -tocopherol, retinyl palmitate, β -carotene, and co-enzyme Q10) were determined by HPLC with electrochemical detection, plasma malondialdehyde (MDA) by HPLC with fluorescence detection, plasma cytokines (interleukin (IL)-1 β , IL-5, IL-6, IL-8, IL-10, tumour necrosis factor (TNF) and interferon (INF)- γ) and immunoglobulins (IgE, IgG and IgM) by flow cytometry and urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels by ELISA assay. Dietary habits were determined by a food frequency questionnaire. Plasma MDA levels were on average 0.031 μ M higher in patients than in controls ($p < 0.05$), and a trend for higher urinary 8-OHdG was observed. Erythrocyte GSH and plasma retinyl palmitate levels, as well as IgG and IgE levels, were higher in patients than in controls as well (on average 93.707 μ g/ml, 0.006 μ g/ml, 301.555 μ g/ml and 125.004 μ g/ml, resp., $p < 0.05$). Finally, a trend for lower plasma IL-5 levels was observed. After Bonferroni correction for multiple testing, the difference in GSH levels remained statistically significant (nominally significant for retinyl palmitate), while significance was lost for MDA, IgG and IgE levels. Dietary habits do not appear to cause the observed differences. These results point at the potential involvement of slight oxidative stress and immune disturbances in ADHD.

Keywords ADHD · Oxidative stress · Antioxidants · Immunity · Diet

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a disorder characterised by developmentally inappropriate levels of impulsive behaviour, hyperactivity and/or inattention [1, 2]. It is one of the most prevalent chronic paediatric neurodevelopmental conditions, with a worldwide pooled prevalence in children and youth of 5.29% [3, 4].

ADHD is a multifactorial disorder, influenced by genetic, environmental, biochemical and psychological factors, including common genetic variants underlying other neurodevelopmental and psychiatric disorders such as schizophrenia and depression, as well as health risk behaviours such as smoking and obesity. This indicates a shared genetic basis across these traits, but no straightforward indication can yet be given about the exact pathophysiology of ADHD [5–7]. Dopaminergic and noradrenergic dysfunctions are involved [5], but ADHD is also associated with immune

✉ Annelies A. J. Verlaet
annelies.verlaet@uantwerpen.be

¹ Natural Products and Food Research & Analysis (NatuRA), Department of Pharmaceutical Sciences, University of Antwerp, Annelies Verlaet, Universiteitsplein 1, 2610 Wilrijk, Belgium

² Paediatric Neurology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium

³ STATUA, University of Antwerp, Prins Boudewijnlaan 43, 2650 Edegem, Belgium

⁴ Cell Biology and Immunology Group, Wageningen University, P.O. Box 338, 6708 WD Wageningen, The Netherlands

and oxidative imbalances as reviewed recently [8]. Various studies demonstrate increased levels of oxidative damage markers and decreased activity of antioxidant enzymes in ADHD [9–12]. In addition, ADHD has a high comorbidity with both T_H1 - and T_H2 -mediated disorders [13–18]. Moreover, sub-cortical volumetric reductions have been found in ADHD, which, based on gene expression profiles, can be partly explained by increased vulnerability of these regions to apoptosis, oxidative stress and autophagy [19]. Oxidative and immune mechanisms may contribute to ADHD via neuronal damage and abnormal neurotransmitter regulation, but decisive evidence on their exact contributions to this disorder is yet to be published [18, 20, 21]. Results are often inconsistent and immune markers other than antibodies, such as cellular activation and cytokine levels, have not been systematically studied in ADHD [10–12, 22–24]. A thorough investigation of oxidative and immune aberrancies and their interconnection in ADHD is thus needed. In this study, biomarkers of antioxidant status (erythrocyte glutathione (GSH) and plasma retinol, α -tocopherol, γ -tocopherol, retinyl palmitate, β -carotene, and co-enzyme Q10 (coQ10)), oxidative damage (plasma malondialdehyde (MDA) and urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG)) and immune status (plasma cytokines (interleukin (IL)-1 β , IL-5, IL-6, IL-8, IL-10, tumour necrosis factor (TNF), and interferon (INF)- γ) and immunoglobulins (IgA, IgE, IgG, and IgM)) were compared between ADHD patients and controls without ADHD. It is hypothesised that ADHD patients have more oxidative damage and a disturbed immune balance.

Methods

Participants

A comparison was conducted between untreated ADHD patients (cases) from the paediatric outpatient department of Child Neurology of the Antwerp University Hospital (UZA) and controls without ADHD from ten random schools in Flanders (Belgium). Patients were diagnosed with ADHD according to DSM-4 or DSM-5 criteria by experienced staff [1, 2]. All participants were 6–12 years old, had no diagnosis of autism-spectrum disorder or chronic systemic disorder (e.g. diabetes or epilepsy), and no severe mental conditions, IQ < 70, or pervasive developmental disorder. Subjects were excluded if they had used medication or nutritional supplements for more than 1 week during the previous 3 months. Participants were recruited between June 2013 and September 2017 via a letter in schools and UZA and a poster in UZA waiting rooms. All participants and their legally accepted representative agreed with and signed the written informed consent. Upon inclusion, participants received a randomly assigned participation code.

Sample size calculation was based on SD values in previous studies [12, 18]. It was determined that 63 children per group were required to demonstrate group differences of 0.5 SD regarding the proposed biomarkers (power 0.80, significance level 0.05).

This study was approved by the UZA Ethical Committee (approved study number: 13/18/209; Belgian registration number: B300201317799) and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Sample collection

Blood was collected in EDTA tubes (BD, USA) and placed on ice immediately. After centrifugation (2000 g, 4 °C, 10 min), erythrocytes and plasma were frozen in – 70 °C and stored until analysis. Urine was collected in sterile urine containers, placed on ice immediately and stored at – 70 °C until analysis.

Questionnaires

Parents were asked to fill out several questionnaires. The Social-Emotional Questionnaire (SEQ) focusses on ADHD and on social behavioural problems, anxiety and autism, with items covering core symptoms according to the DSM-4 or DSM-5 [25]. Items are rated on a five-point scale, concerning the past 6 months: never, less than once a month, every month, every week, or (almost) every day. Dietary habits of participants were assessed by an unpublished food frequency questionnaire (FFQ) concerning seven food groups: fruits, vegetables, cereal and potato products, dairy, meat and fish, drinks, and miscellaneous. Items were rated on a five-point scale: never or less than once a month, once to three times a month, once a week, twice to five times a week, or (almost) every day. This FFQ was based upon a FFQ assessing infant dietary habits in an unpublished pilot study [26]. The original FFQ consisted of questions on meal frequency (breakfast, lunch and dinner) and food frequency (60 questions on the intake of seven food groups, including portion sizes), which were rated on a six-point scale (never or less than once a month, once to three times a month, once a week, twice to four times a week, five to six times a week or every day). Fifteen additional questions assessed more specific information, e.g. bread type. Comparison of this FFQ to a 3-day food diary, the gold standard to investigate dietary habits, revealed acceptable validity, but potential overestimation of vegetable and potato product intake. For the present FFQ, 35 questions were extracted from the original FFQ as well as additional questions on, e.g. type of bread, without questions on portion size. The rating scale was slightly adapted as well. Researchers involved in

digitalizing questionnaire answers, calculating scores and statistics were blinded for the participant groups.

Biological analyses

Technicians blinded for the participant groups performed biological analyses for patients and controls concurrently.

Erythrocyte GSH content, the most important intracellular antioxidant, was analysed after sample haemolysis and purification by a validated HPLC method [27, 28]. The lipid-soluble antioxidants α - and γ -tocopherol, β -carotene, retinol, retinyl palmitate and coQ10 are non-enzymatic defence mechanisms against oxidants [29–32]. Therefore, plasma levels of these antioxidants were analysed by a validated HPLC method after extraction with hexane [33]. GSH and the lipid-soluble antioxidants were analysed on an Agilent 1260 HPLC system (Agilent Technologies, Belgium) with an ESA-5600A CoulArray 8-channel electrochemical detector (ESA, Thermo Fisher Scientific, USA).

Oxidative damage to fatty acids leads to the generation of reactive aldehydes such as MDA. Plasma MDA was determined by a validated HPLC method on an Agilent 1260 HPLC system (Agilent Technologies, Belgium) with a Jasco FP-1520 fluorescence detector (Jasco, The Netherlands) [33]. Urinary 8-OHdG has been validated as a biomarker of oxidative DNA damage, though produced from both DNA guanine bases and nucleotides in cellular pools by nucleotide excision repair, and was analysed by a competitive enzyme-linked immunosorbent assay (ELISA) kit (NWLSS™ Urinary 8OHdG ELISA, Northwest Life Science Specialties, USA) according to the manufacturer's protocol [34–36]. Urinary 8-OHdG concentration was expressed as ng/mg creatinine. Urinary creatinine levels were analysed by the Creatinine Microplate Assay (Oxford Biomedical Research, USA) according to the manufacturer's protocol.

Plasma cytokine levels (IL-1 β , IL-5, IL-6, IL-8, IL-10, TNF, and IFN- γ) were determined by the Cytometric Bead Array (CBA) Human Soluble Protein Master Buffer Kit, and plasma IgA, IgM and IgG levels by the CBA Human Ig Flex Set (BD, USA) by flow cytometry (FACSCanto™ II, BD, USA) according to the manufacturer's protocol. Total

plasma IgE levels were determined by ImmnoCAP 250 analysis (Thermo Fisher Phadia, Sweden).

Statistical analyses

SPSS version 23.0.0.0 was used for statistical analyses. Data were checked for outliers and normality, and presented as mean \pm standard deviation (SD) or median \pm interquartile range (IQR). Differences between patients and controls were tested for significance by independent samples *t* test, Mann–Whitney U, chi-square or Cochran–Armitage trend tests, or by multiple regression analysis. Bonferroni correction for multiple testing was performed. For all regression models, residuals versus the predicted values were plotted to check the assumptions of linearity and homoskedasticity. Using QQ-plots, the normality of the residuals was checked. A *p* value < 0.05 is considered significant.

Results

In total, 126 participants were included in this comparison: 57 ADHD patients and 69 controls. No significant differences were found between patients and controls regarding the demographic variables such as age, height and weight (independent samples *t* tests, Table 1) and also gender ratio was not significantly different (chi-square test). Participants were mainly Caucasian (84% in the patient group, 86% in the control group).

Questionnaires

The median scores on all SEQ conditions and subconditions (Table 2) were significantly higher in the ADHD group than in controls ($p < 0.05$), except for social anxiety (Mann–Whitney *U* tests).

A trend was noticed for more physician's diagnosed allergies as reported by parents in patients than in controls (23.1% vs. 11.8%, $\chi(1) = 2.715$, $p = 0.099$). Suspicion of undiagnosed allergy by parents, the use of antibiotics and the prevalence of ear infections were not significantly

Table 1 Demographic variables per group

	ADHD	Control	Test value	<i>P</i> value (two sided)
Age (years; mean \pm SD)	8.98 \pm 1.75	8.37 \pm 1.69	$T(121) = -1.959$	0.052
Height (<i>m</i> ; mean \pm SD)	1.36 \pm 0.11	1.36 \pm 0.12	$T(114) = -0.105$	0.916
Weight (kg; mean \pm SD)	32.54 \pm 9.48	31.15 \pm 7.64	$T(114) = -0.878$	0.382
Gender (<i>n</i> ; male/female)	41/16	45/24	$\chi(1) = 0.649$	0.420

SD standard deviation

Table 2 Median scores and IQR per (sub)condition of SEQ

	ADHD		Control		Test value	P value (2 sided)
	Median	IQR	Median	IQR		
ADHD total	40.0	22.8	12.0	11.5	$U=329.5$	< 0.001*
ADHD inattention	15.0	8.0	4.0	4.0	$U=199.5$	< 0.001*
ADHD hyperactivity	16.0	12.5	5.0	6.0	$U=664.0$	< 0.001*
ADHD impulsivity	9.0	8.5	4.0	4.8	$U=649.0$	< 0.001*
Autism	6.0	6.0	2.0	2.3	$U=827.5$	< 0.001*
Social problem behaviour total	17.0	19.0	10.0	11.0	$U=963.0$	< 0.001*
Oppositional defiant disorder	7.0	12.5	4.0	4.8	$U=1168.5$	< 0.001*
Conduct disorder—aggression	1.0	3.8	0.0	2.0	$U=1393.5$	0.004*
Conduct disorder—antisocial	9.0	8.0	4.0	6.0	$U=928.0$	< 0.001*
Anxiety total	16.5	16.0	7.0	10.0	$U=982.5$	< 0.001*
General anxiety	6.0	6.0	3.0	4.0	$U=902.5$	< 0.001*
Social anxiety	3.0	6.5	3.0	3.9	$U=1621.0$	0.114
Depression	5.0	5.0	2.0	4.0	$U=1017.5$	< 0.001*

IQR interquartile range

*Statistically significant if $p < 0.05$

different between both groups ($p > 0.05$, chi-square tests, data not shown).

Regarding most items, dietary habits of patients and controls appeared very similar, except for consumption of sweet milk drinks and fish, which appeared less in patients ($p < 0.05$, Cochran–Armitage trend tests, data not shown). No significant difference was observed in percentages of participants meeting recommendations for daily fruit (55.6% in ADHD vs. 48.5% in controls) and vegetable intake (63.0% vs 70.6%).

Biological analyses

Mean levels and SD of each analysed oxidative damage and antioxidant biomarker are presented per group in Table 3, those of each analysed immune biomarker in Table 4. A comparison of these levels between groups must account for different processing times as a potential confounder (processing time of each sample type can be found per group in Table 5), as processing time could influence biomarker levels. Therefore, a linear regression model was fitted with the biomarker as outcome variable, disease status as predicting variable and processing time as covariate. The adjusted differences between both groups can be found in Tables 3 and 4 as well. For example,

Table 3 Mean levels and SD for oxidative damage and antioxidant biomarkers in ADHD patients and controls and adjusted mean difference, accounting for processing time, by linear regression

	ADHD		Control		Adjusted difference	95% CI	Test value	P value (2 sided)
	Mean	SD	Mean	SD				
8-OHdG (ng/mg Crn)	13.749	5.168	12.229	4.259	1.851	− 0.290 to 3.992	$F(1116)=2.932$	0.089
MDA (μM)	0.374	0.078	0.348	0.056	0.031	0.004 to 0.058	$F(1118)=5.030$	0.027*
α-Tocopherol (μg/ml)	10.302	2.199	9.708	1.709	0.319	− 0.470 to 1.109	$F(1117)=0.641$	0.425
β-Carotene (μg/ml)	0.590	0.229	0.657	0.267	− 0.020	− 0.118 to 0.079	$F(1118)=0.153$	0.696
γ-Tocopherol (μg/ml)	0.462	0.170	0.420	0.147	0.041	− 0.024 to 0.106	$F(1117)=1.586$	0.210
CoQ10 (μg/ml)	0.578	0.143	0.534	0.134	0.043	− 0.013 to 0.099	$F(1119)=2.337$	0.129
GSH (μg/ml)	805.662	129.761	670.742	112.641	93.707	45.684 to 141.729	$F(1111)=14.951$	<0.001*
Retinol (μg/ml)	0.310	0.043	0.316	0.050	− 0.003	− 0.022 to 0.016	$F(1116)=0.084$	0.772
Retinyl palmitate (μg/ml)	0.019	0.013	0.011	0.008	0.006	0.002 to 0.011	$F(1108)=7.780$	0.006*

CI confidence interval, CoQ10 co-enzyme Q10, Crn creatinine, GSH reduced glutathione, SD standard deviation

*Significantly different if $p < 0.05$

Table 4 Mean levels and SD for immune biomarkers in ADHD patients and controls and adjusted mean difference, accounting for processing time, by linear regression

	ADHD		Control		Adjusted difference	95% CI	Test value	P value (2 sided)
	Mean	SD	Mean	SD				
IFN- γ (pg/ml)	5.802	0.228	5.815	0.291	- 0.031	- 0.139 to 0.078	$F(1116)=0.316$	0.575
IL-1 β (pg/ml)	5.463	0.253	5.480	0.286	- 0.036	- 0.149 to 0.076	$F(1114)=0.406$	0.525
IL-5 (pg/ml)	5.442	0.312	5.603	0.410	- 0.130	- 0.284 to 0.023	$F(1112)=2.819$	0.096
IL-6 (pg/ml)	6.669	0.368	6.669	0.481	- 0.057	- 0.236 to 0.122	$F(1110)=0.403$	0.527
IL-8 (pg/ml)	7.321	1.131	7.291	1.193	0.009	- 0.464 to 0.481	$F(1115)=0.001$	0.972
IL-10 (pg/ml)	5.549	0.528	5.602	0.710	- 0.061	- 0.309 to 0.187	$F(1116)=0.237$	0.627
TNF (pg/ml)	6.308	0.553	6.418	0.492	- 0.102	- 0.304 to 0.101	$F(1120)=0.993$	0.321
IgE (μ g/ml)	250.358	270.350	132.348	158.592	125.004	25.298 to 224.709	$F(197)=0.779$	0.015*
IgG (μ g/ml)	2198.126	985.728	2100.781	116.924	301.555	143.382 to 746.491	$F(1111)=0.182$	0.016*
IgM (μ g/ml)	328.257	190.206	294.117	163.720	17.293	- 54.126 to 88.712	$F(1114)=0.230$	0.632

CI confidence interval, IFN interferon, Ig immunoglobulin, IL interleukin, SD standard deviation, TNF tumour necrosis factor

*Significantly different if $p < 0.05$

Table 5 Mean levels and SD sample processing time for each biological sample in ADHD patients and controls

	ADHD		Control	
	Mean (h)	SD	Mean (h)	SD
Plasma	4.05	3.08	6.82	2.49
Erythrocytes	4.20	2.76	6.80	2.46
Urine	3.93	3.34	6.37	2.93

assuming an equal processing time, erythrocyte GSH level was on average 93.7 μ g/ml higher in patients than in controls ($p < 0.05$). Also plasma retinyl palmitate levels were significantly higher in patients than in controls. Regarding oxidative damage biomarkers, plasma MDA levels were significantly higher in patients, while a trend for higher urinary 8-OHdG levels was observed. Regarding immune biomarkers, plasma IgG and IgE levels were significantly higher in patients ($p < 0.05$), with a trend for lower plasma IL-5 levels ($p < 0.05$, linear regression). Antioxidant levels were not predicted by the amount of oxidative damage (data not shown, linear regression).

As for ADHD patients versus controls, a comparison was made between participants with and without a physician's diagnosed allergy as reported by parents. A linear regression model was fitted with the biomarker as outcome variable, allergy status as predicting variable and processing time as covariate. When accounting for processing time, none of the antioxidant, oxidative damage or immune biomarkers was significantly different between participants with and without allergies ($p > 0.05$, data not shown).

A positive correlation was found between plasma MDA level accounted for processing time and SEQ impulsivity score ($p < 0.05$; Table 6).

Table 6 Correlations (Pearson's r) between oxidative stress biomarkers and ADHD SEQ scores

	ADHD total	Inattention	Hyperactivity	Impulsivity
8-OHdG	0.011	0.001	0.034	0.019
MDA	0.111	0.069	0.079	0.208*
α -Tocopherol	- 0.114	- 0.044	- 0.154	- 0.178
β -Carotene	- 0.008	- 0.021	0.009	- 0.033
γ -Tocopherol	- 0.043	- 0.021	- 0.036	- 0.077
CoQ10	0.051	0.048	0.019	0.047
GSH	- 0.037	- 0.013	- 0.044	- 0.060
Retinol	0.004	0.042	0.040	- 0.042
Retinyl palmitate	0.032	0.011	0.020	0.049
IFN- γ	- 0.037	- 0.057	- 0.001	- 0.072
IL-1 β	0.000	- 0.065	0.053	0.019
IL-5	- 0.144	- 0.157	- 0.127	- 0.132
IL-6	- 0.063	- 0.065	- 0.057	- 0.069
IL-8	- 0.078	- 0.111	- 0.059	- 0.054
IL-10	- 0.121	- 0.104	- 0.096	- 0.140
TNF	- 0.043	- 0.068	- 0.003	- 0.050
IgE	- 0.007	- 0.015	- 0.011	- 0.013
IgG	- 0.109	- 0.098	- 0.101	- 0.100
IgM	- 0.100	- 0.027	- 0.091	- 0.141

CoQ10 co-enzyme Q10, GSH reduced glutathione, IFN interferon, Ig immunoglobulin, IL interleukin, MDA malondialdehyde, TNF tumour necrosis factor

* Statistically significant if $p < 0.05$

Discussion

To the best of our knowledge, this is the first comparison of erythrocyte GSH and plasma CoQ10, retinyl palmitate, IL-5, IL-8 and IgM between ADHD patients and controls. Significantly increased plasma MDA levels were found in ADHD patients compared to controls ($p < 0.05$), as well as a trend for higher urinary 8-OHdG levels. In addition, significantly increased erythrocyte GSH as well as plasma retinyl palmitate were observed in ADHD patients compared to controls, as well as significantly increased total IgE and IgG levels, along with a trend for more diagnosed allergies. Finally, a trend for lower plasma IL-5 levels was observed. After Bonferroni correction for multiple testing, however, only a borderline significant difference was found for retinyl palmitate, while significance was lost for MDA, IgG and IgE levels. Nevertheless, these data are consistent with a potential role of oxidative stress that affects the immune system in children with ADHD compared to controls. As a result, paediatric ADHD patients might develop more IgE- and non-IgE-mediated allergies [15].

Questionnaires

No differences were found in demographic variables between patients and controls. The expected higher scores on various SEQ (sub)conditions in the ADHD group compared to controls, even after Bonferroni correction which takes into account false-positive significant differences due to multiple testing (in this case: 13 conditions and subconditions, so significant if $p < 0.05/13$), is a confirmation of more comorbidity in ADHD, though high comorbidity rates could also be due to selection of the patient group via a university hospital. However, these comorbidities could influence the results of this study.

Dietary habits of patients and controls appeared very similar, as the only significant differences found concerned less consumption of sweet milk drinks and fish by ADHD patients ($p < 0.05$). Again, Bonferroni correction for multiple testing should be taken into account (35 questioned items, so significant if $p < 0.05/35$). Therefore, these differences can be neglected. Though dietary habits can influence oxidative and inflammatory status [37, 38], they probably do not explain differences observed regarding the biomarkers analysed. In addition, similar dietary habits reflect a similar socioeconomic status of both groups, despite different recruitment sources [39].

Oxidative damage

Significantly higher adjusted plasma MDA levels in ADHD patients were observed, while MDA correlated weakly with

the SEQ impulsivity score. Though after Bonferroni correction for multiple testing, significance was lost for the adjusted difference and correlation, these results still indicate a potential involvement of slight oxidative damage in ADHD. Another study, without Bonferroni correction, also reported more plasma MDA in paediatric ADHD, but no correlation with ADHD subtype was found [10]. Other studies, however, found lower plasma or serum MDA levels [23, 24]. Still, increased lipid peroxidation in ADHD is also evidenced by raised urinary acrolein–lysine levels as well as by exhaled ethane levels, a marker of omega-3 fatty acid oxidation [11, 12]. Omega-3 fatty acids are essential in brain development and function [40–42]. Multiple reviews and meta-analyses report small, beneficial effects of $n - 3$ PUFAs (sometimes in combination with $n - 6$ PUFAs) on inattention, hyperactivity, cognition and/or ADHD overall [43–50], but others do not support a therapeutic effect [41, 46, 51–54]. Especially, the duration and composition of supplementation appear of influence on the behavioural effect, with EPA doses of at least 500 mg/day or the combination of $n - 3$ with $n - 6$ PUFAs (γ -linolenic acid (GLA) and EPA, possibly with antioxidants such as vitamin C or E) generating the most promising results [5, 42, 44, 49, 55, 56].

A trend for higher adjusted urinary 8-OHdG levels was observed in ADHD. Literature on oxidative DNA damage in ADHD is contradictory, as increased levels of total DNA damage were found, determined by 8-oxoG in lymphocytes [22], as well as reduced 8-OHdG levels in serum [24].

Considering the strength of the correlations between SEQ scores and biomarkers, especially impulsivity appeared related to higher levels of oxidative lipid damage. This could imply that the ADHD spectrum not only varies in terms of behavioural manifestations, but also regarding underlying mechanisms and thus potentially also appropriate treatment.

Antioxidants

When correcting for processing time, ADHD patients had significantly higher erythrocyte GSH levels than controls, even after Bonferroni correction, though GSH levels did not correlate with any of the SEQ ADHD scores ($p > 0.05$). Higher antioxidant levels do not necessarily imply less oxidative stress, as these could be a compensation mechanism for increased oxidative stress [10]. In fact, levels of GSH S-transferase and GSH peroxidase, both necessary for GSH activities, were found to be lower in ADHD before [10, 18]. These reduced levels, leading to low GSH consumption and thus lack of an efficient antioxidant defence, could also explain higher GSH levels. In a randomised double-blind placebo-controlled trial, administration of a procyanidin-rich extract (1 mg/kg body weight/day) significantly increased whole blood GSH level in paediatric ADHD patients from 0.103 ± 0.019 mM to 0.130 ± 0.008 mM, but no GSH levels

were determined for healthy controls [57]. The striking difference in concentration level between this and the present study (2–3 mM) is probably caused by methodological differences, especially sample type used (whole blood vs. erythrocytes).

Vitamin A, including retinol and retinyl palmitate, is required for various biological events, including cell differentiation and survival. However, excessive vitamin A intake can have negative effects, including redox impairment, mitochondrial dysfunction and neurotoxicity. For instance, *in vitro* as well as *in vivo*, vitamin A possesses antioxidant abilities [58–61], though depending on the dose and other factors (including nutritional status and pathology), it may also exert prooxidative effects, leading to cell death and inflammation [59, 62]. This prooxidant inversion also accounts for other well-known antioxidants, including β -carotene, a vitamin A precursor [58]. In the present study, however, physiological levels have been measured, which can be assumed to exert antioxidant rather than prooxidant effects. As retinyl palmitate is the storage form of vitamin A, and low levels were found in plasma, it is questionable whether the borderline significant difference after Bonferroni correction is biologically relevant. No difference was found for adjusted plasma retinol levels as well as for its precursor β -carotene, as confirmed by Spahis et al. [23]. No difference regarding retinol was observed, but this is not surprising as retinol concentrations in plasma are strictly regulated due to toxicity at high levels [63]. Therefore, the authors doubt that vitamin A is involved in ADHD, irrespective of pro- or antioxidant effects.

Spahis et al. found significantly higher plasma α - and γ -tocopherol levels in ADHD patients [23], but another study, like the present study when accounting for processing time, found no difference regarding serum tocopherol levels [64].

Redox imbalance

Research generally points towards more oxidative damage in ADHD. Although non-enzymatic antioxidant levels generally do not appear reduced in ADHD, despite conflicting results, levels or activities of antioxidant enzymes were found to be lower in various studies [10, 18, 22, 65–70]. Therefore, oxidative damage biomarkers appear more reflective of the actual oxidative stress situation compared to antioxidant levels, since even relatively high antioxidant levels can still be too low to balance high oxidant levels [71].

Immune biomarkers

In patients compared to controls and when accounting for processing time, no significantly different plasma cytokine

levels were found, despite a trend for lower IL-5 levels (without Bonferroni correction). In autism, IL-6 and IFN- γ levels correlated negatively with full-scale IQ, verbal comprehension index and working memory index [72], but these cognitive abilities were not assessed in the present study. Nevertheless, significantly higher adjusted plasma IgG and IgE levels in ADHD were observed (indicating an immune imbalance, though significance was lost after Bonferroni correction), without correlation with any of the SEQ ADHD scores.

Oxidative and inflammatory processes are closely related [18]. An oxidant/antioxidant imbalance is responsible for changes in the nervous and immune system [18, 68, 73–78]. Moreover, immune cells are an important source of both oxidant and proinflammatory compounds, such as reactive oxygen and nitrogen species (ROS and RNS) and inflammatory cytokines, which stimulate NF- κ B activation, leading to production of more oxidants and inflammatory compounds, and thereby establishing a vicious circle [18, 78]. Antioxidants could exert beneficial effects through an improvement of oxidative stress and immune cell functions, and might, therefore, have a potential in ADHD therapy [8].

ADHD-associated increased oxidative stress might, in case of a chronic state, lead to immune dysfunction resulting in elevated T_H2 induction and thereby increased IgE levels. Although IgE is found in every individual, and levels increase with age until reaching a stable level at adulthood, elevated concentrations of total IgE reflect a predisposition to develop IgE-mediated allergic diseases, despite not being directly related to allergic status [79, 80]. Oxidative stress might thus facilitate the development of allergic conditions in ADHD patients [8, 75]. Indeed, the observed higher IgE levels were supported by a trend for more diagnosed allergies in patients than in controls.

It should be noted that the use of medication was an exclusion criterion of this study, so that patients with intense allergy symptoms were likely to be excluded. It is, therefore, no surprise that none of the antioxidant, oxidative damage or immune biomarkers was significantly different between participants with and without allergies or that no significantly aberrant systemic cytokine levels were found, which would indicate active inflammation. In addition, cytokine concentrations in mucosal secretions are predominantly the result of local cytokine production, causing a potential lack of correlation between low plasma IL-5 levels and, presumably, high concentrations in mucosal secretions reflecting local T_H2 expansion [81]. Moreover, as the analysed cytokine levels in both groups were very low, it is questionable whether any observed difference would be biologically relevant. Though elevated oxidative stress can cause higher basal (without antigen stimulation) levels of inflammatory cytokines [82], oxidative stress in ADHD might be too limited for clear effects on plasma cytokine levels.

The shifted immune balance due to oxidative stress results in a modified humoral immune response. Though IgE levels are more strongly T-cell regulated and have a much shorter half-life than IgG, under chronic conditions also IgG levels will be changed [83]. The observed higher IgG levels in ADHD support involvement of inflammation [84].

Due to the use of various methodologies in literature, it is hard to compare the results of different studies. For example, despite the increased prevalence of atopies in ADHD in literature [15, 85], their association appears based on a non-IgE-mediated mechanism [86–89]. In addition, a role for IgG in ADHD pathophysiology was countered before as well [86]. Moreover, indications of more T_H1 cytokines have been found in previous research, e.g. higher detection rates for IFN- γ and TNF- β in cerebrospinal fluid [90]. Another study, however, reports no significant difference regarding serum TNF- α , IL-1 β , IL-6 and IL-10, but did find higher levels of IFN- γ in ADHD patients than in controls [91]. Further research with consistent methodology is thus required to draw a final conclusion. Nevertheless, cytokines could be important in ADHD as they can pass the blood–brain barrier and affect synaptic plasticity and neurogenesis, and can even cause T-cell mediated neuroinflammation [91–93].

Strengths and limitations

This case–control comparison has limitations. For example, the nature of this study does not address the investigation of causality. It is, therefore, unknown whether increased oxidative stress or immune dysbalance is the causative factor in the pathophysiology of ADHD, or a consequence of the disorder [18]. For instance, increased oxidative stress in ADHD could be the result of the restlessness related with ADHD [69]. Still, case–control studies are a good start, though not providing solid proof, to unravel underlying mechanisms of action.

Furthermore, though all included patients in this study were diagnosed by a child neurologist as having ADHD according to DSM criteria (DSM-4 or DSM-5), several patients would not be classified as such based solely on the SEQ scores of their parents. In addition, several controls had a positive SEQ ADHD score, without ADHD diagnosis or parental complaints. This underscores the subjectivity of questionnaires and might explain the lack of correlations between biomarkers and SEQ (sub)scores.

Another limitation is that the FFQ questioned consumption frequency but not portion size, which makes it impossible to draw conclusions on actual intake. In addition, the probability of recall bias and overestimation of vegetable and potato product intake should be taken into account [26], but both are not expected to differ between patients and controls.

An important strength of this study is the use of regression analysis correcting for differences in processing time

due to practical issues (e.g. sample transport to the analytical facility from the neighbouring UZA was faster than from schools). Systematically recording processing time and correcting for this potential confounder was found to be crucial to obtain valid results and should thus be implemented in future research. In addition, Bonferroni correction for multiple testing is essential, but often not performed in literature.

Finally, the comparison of erythrocyte GSH and plasma CoQ10, retinyl palmitate, IL-5, IL-8 and IgM between ADHD patients and controls has not been published before.

Conclusion

An evaluation of redox and immune status in ADHD was performed. Significantly higher plasma MDA levels were found in ADHD patients compared to controls, and a trend for higher urinary 8-OHdG levels. Erythrocyte GSH and plasma retinyl palmitate as well as plasma IgG and IgE levels were significantly higher in patients than in controls. Finally, a trend for lower plasma IL-5 levels was observed. After Bonferroni correction for multiple testing, the result for GSH remained statistically significant, while only a borderline significant difference was found for retinyl palmitate. Significance was lost for MDA, IgG and IgE levels. Still, though only slightly elevated, an indication of more oxidative damage was thus found in ADHD. Antioxidant levels, however, did not differ or were even higher than in the control group. In addition, higher IgE levels were supported by a trend for more diagnosed allergies in patients than in controls and might point at an immune dysbalance in ADHD. However, due to the nature of this study, it is unknown whether oxidative stress and immune dysbalance have a causative role in ADHD. Dietary habits do not appear to explain the observed biomarker differences. Further confirmation of these results is required, as well as further investigation of potential differences between ADHD subtypes. Finally, systematically correcting for processing time is crucial to obtain valid results.

Acknowledgements The Fund for Scientific research (FWO Flanders, Belgium) is acknowledged for the financial support (FWO MAND 2013-11U8314 N). FWO had no role in the study design; the collection, analysis and interpretation of data; writing of the report; and the decision to submit the article for publication. The authors would like to thank Dr. J. Ruinemans-Koerts (Clinical Chemical and Haematological Laboratory, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands) for her help with the antibody analyses.

Compliance with ethical standard

Conflict of interest The authors declare that they have no conflict of interest.

References

1. APA (2013) American Psychiatric Association: DSM-5 attention deficit/hyperactivity disorder fact sheet. <http://www.dsm5.org/Documents/ADHD%20Fact%20Sheet.pdf>. Accessed 8 Feb 2018
2. APA (2000) American psychiatric association: diagnostic and statistical manual of mental disorders, 4th edn. Text Revision, Washington
3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The Worldwide Prevalence of ADHD: a systematic review and meta-regression analysis. *Am J Psychiatry* 164:942–948
4. Bope E, Kellerman D (2013) Attention-deficit/hyperactivity disorder. *Conn's current therapy* [Internet]. Elsevier, Philadelphia, pp 1050–1053
5. Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. *Lancet* 366:237–248
6. Thapar A, Martin J, Mick E, Arias Vásquez A, Langley K, Scherer SW et al (2016) Psychiatric gene discoveries shape evidence on ADHD's biology. *Mol Psychiatry* 21:1202–1207
7. Demontis D, Walters RK, Martin J, Mattheisen M, Damm Als T, Agerbo E, et al. (2018) Discovery of the first genome-wide significant risk loci for ADHD. *Nat Genet.* <https://doi.org/10.1101/145581>
8. Verlaet AAJ, Maasackers CM, Hermans N, Savelkoul HFJ (2018) Rationale for dietary antioxidant treatment of ADHD. *Nutrients* 10:405–424
9. Ng F, Berk M, Dean O, Bush AI (2008) Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. *Int J Neuropsychopharmacol* 11:851–876
10. Ceylan M, Sener S, Bayraktar AC, Kavutcu M (2010) Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 34:1491–1494
11. Ross BM, McKenzie I, Glen I, Bennett CP (2003) Increased levels of ethane, a non-invasive marker of $n - 3$ fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. *Nutr Neurosci* 6:277–281
12. Kawatani M, Tsukahara H, Mayumi M (2011) Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. *Redox Rep* 16:45–46
13. Güngör S, Celiloğlu O, Ozcan O, Raif S, Selimoğlu M (2013) The frequency of celiac disease in attention-deficit hyperactivity disorder. *J Pediatr Gastroenterol Nutr* 56:211–214
14. Minter K, Roberts J, Hooper S, Burchinal M, Zeisel S (2001) Early childhood otitis media in relation to children's attention-related behavior in the first six years of life. *Pediatrics* 107:1037–1042
15. Pelsser LMJ, Buitelaar JK, Savelkoul HFJ (2009) ADHD as a (non) allergic hypersensitivity disorder: a hypothesis. *Pediatr Allergy Immunol* 20:107–112
16. Schmitt J, Buske-Kirschbaum A, Roessner V (2010) Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. *Allergy* 65:1506–1524
17. Tsai SJ (2006) Signal transducer and activator of transcription 6 (STAT6) and attention-deficit hyperactivity disorder: a speculative hypothesis. *Med Hypotheses* 67:1341–1343
18. Ceylan M, Sener S, Bayraktar A, Kavutcu M (2012) Changes in oxidative stress and cellular immunity serum markers in attention-deficit/hyperactivity disorder. *Psychiatry Clin Neurosci* 66:220–226
19. Hess JL, Akutagawa-Martins GC, Patak JD, Glatt SJ, Faraone SV (2017) Why is there selective subcortical vulnerability in ADHD? Clues from postmortem brain gene expression data. *Mol Psychiatry.* <https://doi.org/10.1038/mp.2017.242>
20. Bulut M, Selek S, Gergerlioglu HS, Savas HA, Yilmaz HR, Yuce M et al (2007) Malondialdehyde levels in adult attention-deficit hyperactivity disorder. *J Psychiatry Neurosci* 32:435–438
21. Kerschensteiner M, Meinl E, Hohlfeld R (2009) Neuro-immune crosstalk in CNS diseases. *Neuroscience* 158:1122–1132
22. Chovanová Z, Muchová J, Sivoňová M, Dvořáková M, Zitanová I, Waczulíková I et al (2006) Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. *Free Radical Res* 40:1003–1010
23. Spahis S, Vanasse M, Bélanger SA, Ghadirian P, Grenier E, Levy E (2008) Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. *Prostaglandins Leukot Essent Fatty Acids* 79:47–53
24. Oztop D, Altun H, Baskol G, Ozsoy S (2012) Oxidative stress in children with attention deficit hyperactivity disorder. *Clin Biochem* 45:745–748
25. TestWeb (2013) Sociaal-Emotionele Vragenlijst (SEV): Bohn Stafleu van Loghum. Springer. <http://testweb.bsl.nl/tests/sev/>
26. Jeunen E (2011) Onderzoek naar voedingsproblemen bij preterm geboren kleuters. Katholieke Hogeschool Kempen (Ed), Geel, Belgium
27. Magielse J (2013) Investigation of the biological activity of plant food supplements in animal models: evaluation of the antioxidant efficacy of *Cynara scolymus* and the hepatoprotective activity of *Desmodium adscendens*. University of Antwerp, Antwerp
28. Magielse J, Verlaet A, Breynaert A, Manuel YKB, Apers S, Pieters L et al (2014) Investigation of the in vivo antioxidative activity of *Cynara scolymus* (artichoke) leaf in the streptozotocin-induced diabetic rat. *Mol Nutr Food Res* 58:211–215
29. Conway HH, Henning P, Lerner UH (2013) Vitamin a metabolism, action, and role in skeletal homeostasis. *Endocrine Rev* 34:766–797
30. Naguib Y, Hari SP, Passwater R Jr, Huang D (2003) Antioxidant activities of natural vitamin E formulations. *J Nutr Sci Vitaminol* 49:217–220
31. Littarru GP, Tiano L (2007) Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. *Mol Biotechnol* 37:31–37
32. Molyneux SL, Young JM, Florkowski CM, Lever M, George PM (2008) Coenzyme Q10: is there a clinical role and a case for measurement? *Clin Biochem Rev* 29:71–82
33. Hermans N, Cos P, Vanden Berghe D, Vlietinck A, De Bruyne T (2005) Method development and validation for monitoring in vivo oxidative stress: evaluation of lipid peroxidation and fat-soluble vitamin status by HPLC in rat plasma. *J Chromatogr B* 822:33–39
34. Aruoma OI (1998) Free radicals, oxidative stress, and antioxidants in human health and disease. *JAOCS* 75:199–212
35. Yano T, Shoji F, Baba H, Koga T, Shiraishi T, Orita H, Kohno H (2009) Significance of the urinary 8-OHdG level as an oxidative stress marker in lung cancer patients. *Lung Cancer* 63:111–114
36. Wu LL, Chang P, Wu JT (2004) Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. *Clin Chim Acta* 339:1–9
37. Dondona P, Ghanim H, Chaudhuri A, Dhindsa S, Kim SS (2010) Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. *Exp Mol Med* 42:245–253
38. Folchetti LD, Monfort-Pires M, de Barros CR, Martini LA, Ferreira SRG (2014) Association of fruits and vegetables consumption and related-vitamins with inflammatory and oxidative stress markers in prediabetic individuals. *Diabetol Metab Syndr* 6:22–29
39. Fismen AS, Smith ORF, Torsheim T, Rasmussen M, Pedersen Pagh T, Augustine L, Ojala K, Samdal O (2016) Trends in food

- habits and their relation to socioeconomic status among Nordic adolescents 2001/2002–2009/2010. *PLoS ONE* 11:e0148541
40. Ramakrishnan U, Imhoff-Kunsch B, DiGirolamo AM (2009) Role of docosahexaenoic acid in maternal and child mental health. *Am J Clin Nutr* 89:958S–962S
 41. Gillies D, Sinn JKH, Lad SS, Leach MJ, Ross MJ (2012) Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev* 11(7):CD007986. <https://doi.org/10.1002/14651858.CD007986.pub2>
 42. Sinn N (2008) Nutritional and dietary influences on attention deficit hyperactivity disorder. *Nutr Rev* 66:558–568
 43. Hurt EA, Arnold LE, Lofthouse N (2011) Dietary and nutritional treatments for attention-deficit/hyperactivity disorder: current research support and recommendations for practitioners. *Curr Psychiatry Rep* 13:323–332
 44. Hawkey E, Nigg JT (2014) Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. *Clin Psychol Rev* 34:496–505
 45. Bos DJ, Oranje B, Veerhoek ES, van Diepen RM, Weusten JMH, Demmelmair H, Koletzko B, de Sain-van der Velden MG, Eilander A, Hoeksma M, Durston S (2015) Reduced symptoms of inattention after dietary omega-3 fatty acid supplementation in boys with and without attention deficit/hyperactivity disorder. *Neuropsychopharmacology* 40:2298–2306
 46. Ortega RM, Rodriguez-Rodriguez E, Lopez-Sobaler AM (2012) Effects of omega-3 fatty acids supplementation in behaviour and non-neurodegenerative neuropsychiatric disorders. *Br J Nutr* 107:S261–S270
 47. Grassmann V, Santos-Galduroz RF, Galduroz SCF (2013) Effects of low doses of polyunsaturated fatty acids on the attention deficit/hyperactivity disorder of children: a systematic review. *Curr Neuropsychol* 11:186–196
 48. Schuchardt JP, Huss M, Stauss-Grabo M, Hahn A (2010) Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. *Eur J Pediatr* 169:149–164
 49. Puri BK, Martins JG (2014) Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials. *Prostaglandin Leukotriene Essent Fatty Acids* 90:179–189
 50. Bos DJ, van Montfort SJJ, Oranje B, Durston S, Smeets PAM (2016) Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: What is the evidence? *Eur Neuropsychopharmacol* 26:546–561
 51. Millichap JG, Yee MM (2012) The diet factor in attention-deficit/hyperactivity disorder. *Pediatrics* 129:330–337
 52. Skokauskas N, McNicholas F, Masaud T, Frodl T (2011) Complementary medicine for children and young people who have attention deficit hyperactivity disorder. *Curr Opin Psychiatry* 24:291–300
 53. Matsudaira T, Gow RV, Kelly J, Murphy C, Potts L, Sumich A, Ghebremeskel K, Crawford MA, Taylor E (2015) Biochemical and psychological effects of omega-3/6 supplements in male adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, clinical trial. *J Child Adol Psychopharmacol* 25:775–782
 54. Transler C, Eilander A, Mitchell S, van de Meer N (2010) The impact of polyunsaturated fatty acids in reducing child attention deficit and hyperactivity disorders. *J Atten Disord* 14:232–246
 55. Königs A, Kiliaan AJ (2016) Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment. *Neuropsychiatr Dis Treat* 12:1869–1882
 56. Joshi K, Lad S, Kale M, Patwardhan B, Mahadik SP, Patni B, Chaudhary A, Bhavne S, Pandit A (2006) Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). *Prostaglandin Leukotriene Essent Fatty Acids* 74:17–21
 57. Dvořáková M, Sivoňová M, Trebatická J, Skodáček I, Waczulíková I, Muchová J, Duracková Z (2006) The effect of polyphenolic extract from pine bark, Pycnogenol, on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD). *Redox Rep* 11:163–172
 58. Pravkin SK, Yakusheva EN, Uzbekova DG (2013) In vivo analysis of antioxidant and prooxidant properties of retinol acetate. *Bull Exp Biol Med* 156:220–223
 59. De Oliveira MR (2015) The neurotoxic effects of vitamin A and retinoids. *Ann Brazl Acad Sci* 87:1361–1373
 60. Ciaccio M, Valenza M, Tesoriere L, Bongiorno A, Albiero R, Livrea MA (1993) Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in vivo. *Arch Biochem Biophys* 302:103–108
 61. Schwarz KB, Cox JM, Sharma S, Clement L, Humphrey J, Gleason C, Abbey H, Sehnert SS, Risby TH (1997) Possible antioxidant effect of vitamin A supplementation in premature infants. *J Pediatr Gastroenterol Nutr* 24:408–414
 62. Petiz LL, Girardi CS, Bortolin RC, Kunzler A, Gasparotto J, Rabelo TK, Matté C, Moreira JCF, Gelain DP (2017) Vitamin A oral supplementation induces oxidative stress and suppresses IL-10 and HSP70 in skeletal muscle of trained rats. *Nutrients* 9:353
 63. Olson JA (1993) Vitamin A and carotenoids as antioxidants in a physiological context. *J Nutr Sci Vitam* 39:S57–S65
 64. Landaas ET, Aarsland TIM, Ulvik A, Halmøy A, Ueland PM, Haavik J (2016) Vitamin levels in adults with ADHD. *BJPsych Open* 2:337–384
 65. Çelik K, Erşan E, Erşan S, Bakır S, Dogan O (2013) Plasma catalase, glutathione-S-transferase and total antioxidant activity levels of children with attention deficit and hyperactivity disorder. *Adv Biosci Biotechnol* 4:183–187
 66. Ruchi K, Anil Kumar S, Sunil G, Bashir A, Prabhat S (2011) Antioxidant activity in children with ADHD—a comparison in untreated and treated subjects with normal children. *Int Med J Malaysia* 10:31–35
 67. Russo AJ (2010) Decreased serum Cu/Zn SOD associated with high copper in children with attention deficit hyperactivity disorder (ADHD). *J Central Nervous System Dis* 2:9–14
 68. Kul M, Unal F, Kandemir H, Sarkarati B, Kilinc K, Kandemir SB (2015) Evaluation of oxidative metabolism in child and adolescent patients with attention deficit hyperactivity disorder. *Psychiatry Investig* 12:361–366
 69. Sezen H, Kandemir H, Savik E, Basmacı Kandemir S, Kilicaslan F, Bilinc H, Aksoy N (2016) Increased oxidative stress in children with attention deficit hyperactivity disorder. *Redox Rep* 21:248–253
 70. Guney E, Cetin FH, Alisik M, Tunca H, Torun YT, Iseri E, Taner YI, Cayci B, Erel O (2015) Attention deficit hyperactivity disorder and oxidative stress: a short term follow up study. *Psychiatry Res* 229:310–317
 71. Joseph N, Zhang-James Y, Perl A, Faraone SV (2015) Oxidative stress and ADHD: a meta-analysis. *J Atten Disord* 19:915–924
 72. Sasayama D, Kurahashi K, Oda K, Yasaki T, Yamada Y, Sugiyama N, Inaba Y, Harada Y, Washizuka S, Honda H (2017) Negative correlation between serum cytokine levels and cognitive abilities in children with autism spectrum disorder. *J Intell* 5:19–26
 73. Lopresti AL (2015) Oxidative and nitrosative stress in ADHD: possible causes and the potential of antioxidant-targeted therapies. *ADHD* 7:237–247
 74. Delion S, Chalon S, Hérault J, Guilloteau D, Besnard J-C, Durand G (1994) Chronic dietary α -linolenic acid deficiency alters

- dopaminergic and serotonergic neurotransmission in rats. *J Nutr* 124:2466–2476
75. King MR, Ismail AS, Davis LS, Karp DR (2006) Oxidative stress promotes polarisation of human T cell differentiation toward a T helper 2 phenotype. *J Immunol* 176:2765–2772
 76. Dröge W, Breitkreutz R (2000) Glutathione and immune function. *Proc Nutr Soc* 59:595–600
 77. Furukawa T, Meydani SN, Blumberg JB (1987) Reversal of age-associated decline in immune responsiveness by dietary glutathione supplementation in mice. *Mech Ageing Dev* 38:107–117
 78. Vaziri ND (2008) Causal link between oxidative stress, inflammation, and hypertension. *IJKD* 2:1–10
 79. Martins T, Bandhauer ME, Bunker AM, Roberts WL, Hill HR (2014) New childhood and adult reference intervals for total IgE. *J Allergy Clin Immunol* 133:589–591
 80. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R et al (2008) Allergy diagnostic testing: an updated practice parameter. *Ann Allergy Asthma Immunol* 100:S1–S148
 81. Dugernier TL, Laterre PF, Wittebole X, Roeseler J, Latinne D, Reynaert MS et al (2003) Compartmentalization of the inflammatory response during acute pancreatitis correlation with local and systemic complications. *Am J Respir Crit Care Med* 168:148–157
 82. Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Belló I, Cilio CM, Wong FS et al (2010) Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. *Clin Exp Immunol* 163:33–49
 83. Singer RE, Moss K, Beck JD, Offenbacher S (2009) Association of systemic oxidative stress with suppressed serum IgG to commensal oral biofilm and modulation by periodontal infection. *Antioxid Redox Signal* 11:2973–2983
 84. Abbas AK, Lichtman AH, Pillai S (2015) Cellular and molecular immunology. Elsevier Saunders, Philadelphia
 85. Chen M, Su T, Chen Y, Hsu J, Huang K, Chang W et al (2013) Attention deficit hyperactivity disorder, tic disorder, and allergy: is there a link? A nationwide population-based study. *J Child Psychol Psychiatry* 54:545–551
 86. Pelsser LMJ, Frankena K, Toorman J, Savelkoul HFJ, Dubois AE, Pereira RR et al (2011) Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. *Lancet* 377:494–503
 87. Gaitens T, Kaplan BJ, Freigang B (1998) Absence of an association between IgE-mediated atopic responsiveness and ADHD symptomatology. *J Child Psychol Psychiatry* 39:427–431
 88. McGee R, Stanton WR, Sears MR (1993) Allergic disorders and attention deficit disorder in children. *J Abnorm Child Psychol* 21:79–88
 89. Blank R, Remschmidt H (1994) Hyperkinetic syndrome: the role of allergy among psychological and neurological factors. *Eur Child Adol Psychiatry* 3:220–228
 90. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997) cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. *J Immunol* 159:2994–2999
 91. Oades RD, Dauvermann MR, Schimmelmann BG, Schwarz MJ, Myint A-M (2010) Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism—effects of medication. *Behav Brain Funct* 6:2–14
 92. Buske-Kirschbaum A, Schmitt J, Plessowa F, Romanos M, Weidinger S, Roessner V (2013) Psychoendocrine and psychoneuro-immunological mechanisms in the comorbidity of atopic eczema and attention deficit/hyperactivity disorder. *Psychoneuroendocrinology* 38:12–23
 93. Martino M, Rocchi G, Escelsior A, Fornaro M (2012) Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. *Curr Neuropharmacol* 10:97–123